Loviride

Loviride
Clinical data
Other namesR089439
ATC code
  • None
Identifiers
IUPAC name
  • 2-[(2-Acetyl-5-methylphenyl)amino]-2-(2,6-dichlorophenyl)acetamide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC17H16Cl2N2O2
Molar mass351.23 g·mol−1
3D model (JSmol)
SMILES
  • Clc1cccc(Cl)c1C(Nc2cc(ccc2C(=O)C)C)C(=O)N
InChI
  • InChI=1S/C17H16Cl2N2O2/c1-9-6-7-11(10(2)22)14(8-9)21-16(17(20)23)15-12(18)4-3-5-13(15)19/h3-8,16,21H,1-2H3,(H2,20,23) checkY
  • Key:CJPLEFFCVDQQFZ-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Loviride (also called loveride) was an antiviral drug manufactured by Janssen (now part of Janssen-Cilag) that is active against HIV. Loviride is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that entered phase III clinical trials in the late 1990s but failed to gain marketing approval because of poor potency. It is of clinical significance only in those patients who were enrolled in clinical trials to evaluate loviride (e.g., CAESAR and AVANTI), because in those trials loviride was often given alone and with no companion drug, leading to a high probability of developing reverse transcriptase mutations such as K103N which result in cross-class resistance the NNRTIs efavirenz and nevirapine.

Synthesis

Loviride synthesis: Janssen Pharmaceutica U.S. Patent 5,407,961 (1995).
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.